USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS
The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.
1 - 17 . (canceled)
18 . A method for treating a metabolic disorder in a subject in need thereof, the method comprising orally administering a composition comprising a therapeutically effective amount of bacteria comprising substantially purified Akkermansia to the subject wherein the substantially purified Akkermansia comprises at least 50% of a strain of Akkermansia.
19 . The method according to claim 18 , wherein said metabolic disorder is obesity.
20 . The method according to claim 18 , wherein said metabolic disorder is selected from the group consisting of metabolic syndrome, insulin-deficiency, insulin-resistance related disorder, diabetes mellitus, glucose intolerance, abnormal lipid metabolism, atherosclerosis, hypertension, stroke, non-alcoholic fatty liver disease, dyslipidemia, high cholesterol, elevated triglycerides, sleep apnea, osteoarthritis, neurodegenerative disorder, inflammatory disorder, immune disorder, atherogenic dyslipidemia, and heart disease.
21 . The method according to claim 18 , wherein viable cells of the Akkermansia are administered to the subject.
22 . The method according to claim 18 , wherein the composition is administered one or more times.
23 . The method according to claim 18 , wherein the Akkermansia is co-administered with another probiotic strain and/or with one or more prebiotics.
24 . The method according to claim 23 , wherein the Akkermansia is co-administered with another probiotic strain.
25 . The method according to claim 23 , wherein the Akkermansia is co-administered with one or more prebiotics.
26 . The method according to claim 18 , wherein said metabolic disorder is selected from the group consisting of obesity, insulin-deficiency, and insulin-resistance related disorders.
27 . The method according to claim 18 , wherein the bacteria consist essentially of Akkermansia.
28 . The method according to claim 18 , wherein if the bacteria comprise a mixture of bacterial strains, then at least 50% of the bacterial strains in the composition are Verrucomicrobia, Bacteroidetes, Firmicutes , or Proteobacteria.
29 . The method according to claim 18 , wherein the bacteria further comprise substantially purified Clostridiales.
30 . The method according to claim 18 , wherein the bacteria further comprise substantially purified Clostridium.
31 . The method according to claim 18 , wherein the Akkermansia is lyophilized.
32 . The method according to claim 18 , wherein the composition comprises a coating, wherein the coating does not fully degrade until after it exits the stomach of the subject.
33 . The method according to claim 18 , wherein the composition comprises a mixture of bacterial strains selected from the group consisting of Verrucomicrobia, Bacteroidetes, Firmicutes , and Proteobacteria.
34 . The method according to claim 18 , wherein the bacteria further comprise substantially purified Firmicutes.
35 . The method according to claim 18 , wherein the composition comprises a coating.
36 . The method according to claim 22 , wherein the composition is administered to the subject at least three times a week.
37 . The method according to claim 18 , wherein the Akkermansia is non-viable.